Faculty & Staff Details
|Name:||Krystal Edwards, Pharm.D., BCPS|
|Position:||Associate Professor, Ambulatory Care Division, Dallas VA|
|Bio||Dr. Edwards has been with the School since 2002 and is an Associate Professor specializing in Primary Care on the Dallas/Fort Worth Campus. She has various teaching responsibilities in didactic lectures, case-based learning, and the experiential program. She has also been an invited lecturer at Keio, Kitasato, and Kyoritsu University of Pharmacies in Tokyo, Japan for their Master of Science pharmacy programs as well as served as a preceptor for the Kyoritsu international exchange program at Texas Tech. She has been an invited lecturer at Khon Kaen University of Pharmacy in Khon Kaen, Thailand. Dr. Edwards was the residency program director for the Dallas/Fort Worth PGY2 Ambulatory Care Specialty Residency from 2005 to 2012 and continues to serve as a primary preceptor for the program.
Dr. Edwards completed her Pharmacy Practice Residency at Baptist Memorial Healthcare in Memphis, Tennessee and a Specialty Residency in Primary Care Pharmacy Practice at the University of Tennessee Medical Center in Knoxville, Tennessee. She became a Board Certified Pharmacotherapy Specialist (BCPS) in December 2003. She will be inducted as Fellow of the American College of Clinical Pharmacy in October of 2012.
ASHP Accredited Primary Care Specialty Residency (July 2001 - June 2002)
University of Tennessee Medical Center
ASHP Accredited Pharmacy Practice Residency (July 2000 - June 2001)
Baptist Memorial Health Care
Doctor of Pharmacy (May 2000)
Medical University of South Carolina (MUSC)
Charleston, South Carolina
Bachelor of Science in Pharmacy (May 1998)
Medical University of South Carolina (MUSC)
Charleston, South Carolina
Sept 2002 – Present: Texas (Pharmacist license number: 41128)
July 2000 - July 2006: Tennessee (Pharmacist license number: 11339)
July 1998 – Present: South Carolina (Pharmacist license number: 9705)
Dec 2003 – Present: Board Certified Pharmacotherapy Specialist (BCPS)
June 2002: Diabetes Patient Care Specialty Training (University of Tennessee Health Science Center College of Pharmacy)
May 2002: Asthma Patient Care Specialty Training (University of Tennessee Health Science Center College of Pharmacy)
March 2000: American College of Clinical Pharmacy Anticoagulation Training Program
January 1999 – Present: American Heart Association Basic Life Support
Elected Fellow of the American College of Clinical Pharmacy 2012
TTUHSC School of Pharmacy 2010-2011 Dallas Campus Faculty Preceptor of the Year
Dr. Edwards' research interests include diabetes, heart failure, and primary and secondary cardiovascular risk factor reductions (e.g. hypertension, hyperlipidemia, heart failure, anticoagulation, metabolic syndrome, and diabetes).
Dr. Edwards currently practices at the Veterans Affairs North Texas Health Care System in the Ambulatory Care Outpatient Clinic in Fort Worth. There, she actively participates in Collaborative Drug Therapy Management (CDTM) to manage patients in the areas of diabetes mellitus, hypertension, heart failure, coronary artery disease, and hyperlipidemia. She has a drug therapy management protocol to allow her to have prescriptive authority to manage patient’s care. It is at this site that she precepts pharmacy residents and third and fourth year doctor of pharmacy students from the Texas Tech University Health Sciences Center School of Pharmacy experiential programs.
Dr. Edwards is actively involved in several organizations including the American College of Clinical Pharmacy (ACCP), the American Society of Health System Pharmacists (ASHP), the Texas Society of Health System Pharmacists (TSHP), the Dallas/Fort Worth ACCP Chapter and the National Lipid Association (NLA). She has served ACCP locally as the Membership Chair, Education Coordinator, and Secretary of the Dallas/Fort Worth ACCP Chapter. She has served nationally on the networking and education committees for the Ambulatory Care practice research network and has chaired the networking and nominations committee for the Endocrine & Metabolism practice research network for 2 years. She has served as the past Secretary/Treasurer and Chair for the Endocrine & Metabolism practice research network. She was on the ACCP Task Force on Residencies for 2010-11 and was the Chair for the Publications Committee in 2011-12. Dr. Edwards has served as a practitioner surveyor for ASHP accreditations of PGY2 Ambulatory Care Residency programs. She is also active in the Dallas American Diabetes Association (ADA) where she serves on the planning committee for the local ADA camps. Dr. Edwards has been a member of the Southwestern Residency Leadership Conference Advisory Council.
• Greene RS, Rangel RM, Edwards KL, Chastain LM, Brouse SD, Alvarez CA, Collins LJ, Brilakis ES, Banerjee S. Ranolazine for the treatment of refractory angina in a veterans population. Cardiovascular Revascularization Medicine. 2011; Available online ahead of print 18 August 2011.
• Edwards KL, Chastain LM, Snodgrass L, Martin A, Busti AJ. Effects of combined use of antiretroviral agents and atypical antipsychotics on lipid parameters. J Antivir Antiretrovir 2011;3:034-039.
• Alvarez CA, Russell NM, Edwards KL, Greene RS, Chastain, LM, Wiedeman RA, Busti AJ. Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) Concentration in a Veterans Affairs patient population. Journal of Clinical Lipidology. 2008:2;447-452.
• Chastain LM, Bain AM, Edwards KL, Bedimo R, Busti AJ. A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia. Journal of Clinical Lipidology. 2007;1:634-639.
• Greene RS, Quinones ME, Edwards KL. Evaluation of thiazide diuretic use as preferred therapy in uncomplicated essential hypertension patients. Pharmacy Practice 2007;5:130-134.
Critical Reviews / Case Reports / Opinion Papers
• Edwards KL, Stapleton M, Weis J, Irons BK. An update in incretin-based therapy: A focus on glucagon-like peptide 1 receptor agonists. Diabetes Technology and Therapeutics. 2012 (Accepted/In-press)
• Irons BK, Weis J, Stapleton M, Edwards KL. An update in incretin-based therapy: A focus on dipeptidyl peptidase - 4 inhibitors. Current Diabetes Reviews. 2012;8:169-182.
• Edwards KL, Riche DM, Stroup JS, Goldman-Levine JD, Padiyara RS, Cross LB, Kane MP. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy. 2010;30:955-965.
• Edwards KL, Alvarez C, Irons BK, Fields J. Third line agent selection for patients with type 2 diabetes uncontrolled on sulfonylurea and metformin therapy: a review of the literature. Pharmacotherapy. 2008;28:506–521.
• Edwards KL, Hall RG, Ceja ME. Gatifloxacin- induced hyperglycemia: a review of four cases and the literature. Journal of Pharmacy Practice. 2007:20:93-102.
• Edwards KL, Irons BK, Xu T. Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications. Pharmacy Practice. 2006; 4:129-133.
• McCall KL, Craddock D, Edwards K. Effect of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes: a reviewed and pooled analysis. Pharmacotherapy. 2006;26:1297-1306.
• Irons B, Greene R, Mazzolini T, Edwards K, Sleeper R. Implications of current thiazolidinediones and cardiovascular risk in type 2 diabetes. Pharmacotherapy. 2006;26:168-81.